Cancer Treatment Reviews
Volume 36, Issue 3 , Pages 249-261 , May 2010

Adjuvant aromatase inhibitor therapy: Outcomes and safety

  • Wolfgang Janni

      Affiliations

    • Klinikdirektor der Frauenklinik, Klinikum der Heinrich Heine Universität, Moorenstr. 5, 40225 Düsseldorf, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 211 81 17500; fax: +49 890211 811 840 7.
    • ,
  • Philip Hepp

      Affiliations

    • Assistenzarzt – Studienzentrale, Frauenklinik der Heinrich Heine Universität Moorenstr. 5, 40225 Düsseldorf, Germany

Received 11 August 2009 ,Revised 14 December 2009 ,Accepted 17 December 2009.

References 

  1. Thürlimann B, Keshaviah A, Coates AS, et al. Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–2757
  2. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ GroupForbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45–53
  3. Coombes RC, Kilburn LS, Snowdon CF, et al. Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559–570
  4. Jonat W, Hilpert F, Kaufmann M. Aromatase inhibitors: a safety comparison. Expert Opin Drug Saf. 2007;6:165–174
  5. Aiello EJ, Buist DS, Wagner EH, et al. Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res Treat. 2008;107:397–403
  6. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25:486–492
  7. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361:766–776
  8. Jones SE, Seynaeve C, Hasenburg A, et al. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast. Cancer Res. 2009;69:67s;[abstract 15]
  9. Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol. 2007;25:2664–2670
  10. Jakesz R, Gnant M, Greil R, et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG trial 8. Breast Cancer Res Treat. 2005;94(Suppl. 1):S10;[abstract 13]
  11. Jakesz R, Gnant M, Greil R, et al. Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8. Cancer Res. 2009;69(Suppl.):67s;[abstract 14]
  12. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–1271
  13. Jakesz R, Greil R, Gnant M, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group trial 6a. J Natl Cancer Inst. 2007;99:1845–1853
  14. Mansell J, Monypenny IJ, Skene AI, et al. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat. 2009;117:91–98
  15. Lamerato L, Havstad S, Gandhi S, Jones D, Chlebowski R. Breast cancer recurrence and related mortality in US pts with early breast cancer. J Clin Oncol. 2005;23(16S):62s;[abstract 738]
  16. Howell A, Cuzick J, Baum M. Et al. ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–62
  17. Thürlimann B. For the BIG 1-98 Collaborative and International Breast Cancer Study Groups. Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer: update of the BIG 1-98 primary core analysis (PCA). In: Primary therapy of early breast cancer 2009, 11th international conference, March 11–14, St. Gallen, Switzerland [abstract 0161].
  18. Chapman JA, Meng D, Shepherd L, et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst. 2008;100:252–260
  19. Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 2008;26:1948–1955
  20. Mackey JR, Joy AA. Skeletal health in postmenopausal survivors of early breast cancer. Int J Cancer. 2005;114:1010–1015
  21. International Osteoporosis Foundation. Osteoporosis in the European community: action plan. A report of the key next steps towards a Europe free from fragility fractures. November 2003. <http://www.iofbonehealth.org/publications.html>; 2009 [accessed 23.07.09].
  22. Rubin CD. Emerging concepts in osteoporosis and bone strength. Curr Med Res Opin. 2005;21:1049–1056
  23. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ GroupBuzdar A, Howell A, Cuzick J, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006;7:633–643
  24. Shapiro CL. Aromatase inhibitors and bone loss: risks in perspective. J Clin Oncol. 2005;23:4847–4849
  25. Goss PE, Qi S, Cheung AM, et al. Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res. 2004;10:5717–5723
  26. McCaig FM, Renshaw L, Williams I, et al. A randomized study of the effects of anastrozole (A), letrozole (L) and exemestane (E) on bone turnover. Cancer Res. 2009;69:148s;abstract 1145
  27. Hadji P, Ziller M, Kieback D, et al. Cancer Res. 2009;69:148s;[abstract 1143]
  28. Coleman RE, Banks LM, Girgis SI, et al. Intergroup Exemestane Study group. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007;8:119–127
  29. Jones SE, Cantrell J, Vukelja S, et al. The effect of tamoxifen (T) or exemestane (E) on bone mineral density (BMD) after 1 year of adjuvant treatment of postmenopausal women with early breast cancer. J Clin Oncol. 2005;23(16S):31s;[abstract 610]
  30. Geisler J, Lonning PE, Krag LE, et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer. 2006;42:2968–2975
  31. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000;18:1570–1593
  32. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006;24:3629–3635
  33. Reginster JY. The high prevalence of inadequate serum vitamin D levels and implications for bone health. Curr Med Res Opin. 2005;21:579–586
  34. Lonning P, Geisler J, Krag LE, et al. Vitamin D deficiency a threat to bone health in breast cancer patients during adjuvant treatment with aromatase inhibitors. J Clin Oncol. 2006;24(18S):16s;[abstract 554]
  35. Lester JE, Dodwell D, Purohit OP, et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res. 2008;14:6336–6342
  36. Van Poznak C, Hannon RA, Clack G, et al. The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study 12-month analysis. Breast Cancer Res Treat. 2007;106(1):S37;[abstract 502]
  37. Brufsky A, Dong M, Lund K, et al. Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). Breast Cancer Res Treat. 2006;100(1):S233;[abstract 5060]
  38. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25:829–836
  39. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer. 2008;112:1001–1010
  40. Brufsky A, Bosserman L, Caradonna R, et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 36-month follow-up. Breast Cancer Res Treat. 2007;106(1):S8;[abstract 27]
  41. Eidtmann H, Bundred NJ, DeBoer R, et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. Cancer Res. 2009;69:74s;[abstract 44]
  42. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005;23:619–629
  43. Hadji P, Aapro M, Brufsky A, et al. Practical guidance for the prevention of aromatase inhibitor-associated bone loss in women with breast cancer. Ann Oncol. 2008;19:1407–1416
  44. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008;19:420–432
  45. Hadji P, Bundred N. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer. Semin Oncol. 2007;34(6 Suppl. 4):S4–S10
  46. Thorne C. Management of arthralgias associated with aromatase inhibitor therapy. Curr Oncol. 2007;14(Suppl. 1):S11–S19
  47. American Heart Association. Heart disease and stroke statistics—2009 update. Dallas, TX. American Heart Association. <http://www.americanheart.org/downloadable/heart/1240250946756LS-1982%20Heart%20and%20Stroke%20Update.042009.pdf>; 2009 [accessed 23.07.09].
  48. European Cardiovascular Disease Statistics. 2005 ed. <http://www.ehnheart.org/files/statistics%202005-092711A.pdf>; 2009 [accessed 22.07.09].
  49. Joensuu H, Ejlertsen B, Lonning PE, Rutqvist LE. Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta Oncol. 2005;44:23–31
  50. Howell A, Cuzick J. Vascular effects of aromatase inhibitors: data from clinical trials. J Steroid Biochem Mol Biol. 2005;95(1–5):143–149[Erratum in: J Steroid Biochem Mol Biol 2006;98(2–3):180]
  51. Aromatase inhibitors in early breast cancer therapy. Semin Oncol 2004;31(6 Suppl. 12):9–14.
  52. Herrington DM, Klein KP. Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Womens Health Issues. 2001;11:95–102
  53. McCaig FM, Renshaw L, Williams L, et al. A randomised study comparing the effects of anastrozole and letrozole on lipid metabolism. Cancer Res. 2009;69:150s–151s[abstract 1152]
  54. McCloskey EV, Hannon RA, Lakner G, et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer. 2007;43:2523–2531
  55. Perez EA. The balance between risks and benefits: long-term use of aromatase inhibitors. Eur J Cancer Suppl. 2006;4:16–25
  56. Markopoulos C, Polychronis A, Dafni U, et al. Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy. Ann Oncol. 2009;20:49–55
  57. Hori Y, Akizuki M, Nishimura R. Comparison of adverse effects of lipid metabolism of anastrozole with tamoxifen in adjuvant setting for postmenopausal women with early breast cancer. Eur J Cancer Suppl. 2006;4:94;[abstract 172]
  58. Wasan KM, Goss PE, Pritchard PH, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol. 2005;16:707–715
  59. Markopoulos C, Chrissochou M, Michailidou A, et al. Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5–7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. Anticancer Drugs. 2005;16:879–883
  60. Arimidex® anastrozole tablets. Prescribing information. AstraZeneca Pharmaceuticals LP, December 2008.
  61. Mouridsen H, Keshaviah A, Coates AS, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol. 2007;25:5715–5722
  62. Bradbury BD, Lash TL, Kaye JA, Jick SS. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina. Cancer. 2005;103:1114–1121
  63. Nordenskjold B, Rosell J, Rutqvist LE, et al. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst. 2005;97:1609–1610
  64. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–1388
  65. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001;93:684–690
  66. Geiger AM, Chen W, Bernstein L. Myocardial infarction risk and tamoxifen therapy for breast cancer. Br J Cancer. 2005;92:1614–1620
  67. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18:937–947
  68. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–1717.
  69. Cuppone F, Bria E, Verma S, et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer. 2008;112:260–267
  70. Sourander L, Rajala T, Raiha I, Makinen J, Erkkola R, Helenius H. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet. 1998;352:1965–1969[Erratum in: Lancet 1999;353:330]
  71. Monnier A, Sakek N, Aladen S. Comparing AI cardiovascular safety data: trial comparators and outcomes. Ann Oncol 2006;17(Suppl. 9):ix100 [abstract 266P].
  72. Medicines and Healthcare Products Regulatory Agency (MHRA). Publication assessment report Femara 2.5Mg tablet, 2006. <http://www.mhra.gov.uk/home/groups/l-unit1/documents/websiteresources/con2023055.pdf>; 2009 [accessed 23.07.09].
  73. Grundy SM, Cleeman JI, Merz CN, et al. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol. 2004;24:e149–e161
  74. Ewer MS, Glück S. A woman’s heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer. 2009;115:1813–1826
  75. Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgias. J Clin Oncol. 2001;19:2767
  76. Mackey J, Gelmon K. Adjuvant aromatase inhibitors in breast cancer therapy: significance of musculoskeletal complications aromatase inhibitors and musculoskeletal complications. Curr Opin Oncol. 2007;10(1):S9–S18
  77. Garreau JR, Delamelena T, Walts D, Karamlou K, Johnson N. Side effects of aromatase inhibitors versus tamoxifen: the patients’ perspective. Am J Surg. 2006;192:496–498
  78. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25:3877–3883
  79. Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome. Breast. 2007;16:223–234
  80. Renshaw L, McHugh M, Williams L, et al. Comparison of joint problems as reported by patients in a randomised adjuvant trial of anastrozole and letrozole. Breast Cancer Res Treat. 2007;106(1):S108–S109[abstract 2072]
  81. Briot K, Bastit L, Rotarsky M, et al. Effects of switching aromatase inhibitors on arthralgia: the ATOLL study. Cancer Res. 2009;69(l):147s–148s[abstract 1142]
  82. Cuzick J, Sestak I, Cella D, Fallowfield L. ATAC Trialists’ Group. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol. 2008;9:1143–1148
  83. Arora A, Potter JF. Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer. J Am Geriatr Soc. 2004;52:611–616
  84. Tralongo P, Dimari A, Repetto L. Aromatase inhibitors and mental function. J Am Geriatr Soc. 2005;53:166
  85. Schilder CM, Schagen SB. Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature. Minerva Ginecol. 2007;59:387–401
  86. Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology. 2004;13:61–66
  87. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000;64:165–176
  88. Schilder M, Eggens PC, Boogerd W, et al. Neuropsychological sequelae of tamoxifen and exemestane after AC-chemotherapy in postmenopausal women with early breast cancer. J Clin Oncol 2007;25(18S):56s [abstract 1099].
  89. Schilder CM, Seynaeve C, Linn SC, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with early breast cancer results from the TEAM trial neuropsychological side study. Cancer Res. 2009;69(Suppl.):144s–145s[abstract 1133]
  90. Schilder CM, van Dam F, Boogerd WS, et al. Prevalence of cognitive complaints is not higher in postmenopausal breast cancer patients before adjuvant hormonal therapy compared to healthy controls. Breast Cancer Res Treat. 2007;106(1):S76;[abstract 1099]
  91. Asmar L, Cantrell J, Vukelja SJ, et al. Final analysis of a planned comparison of menopausal symptoms in 1618 patients receiving either exemestane (E) or tamoxifen (T) in a blinded adjuvant hormonal study. Breast Cancer Res Treat. 2005;95(1):S97;[abstract 2039]
  92. Bender CM, Sereika SM, Brufsky AM, et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause. 2007;14:995–998
  93. Rugo HS, Ahles T. The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. Semin Oncol. 2003;30:749–762
  94. Duffy S, Jackson TL, Lansdown M, et al. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod. 2006;21:545–553
  95. Thomas RJ, Marshall CJ, Williams M, Walker LG. Does switching to letrozole improve hot flushes mood and quality of life in tamoxifen intolerant patients?. Breast Cancer Res Treat. 2005;94(1):S107;[abstract 2067]
  96. Aromasin® exemestane tablets. Prescribing Information. Pfizer, Inc., February 2007.
  97. Whelan TJ, Pritchard KI. Managing patients on endocrine therapy: focus on quality-of-life issues. Clin Cancer Res 2006;12(3 Pt 2):1056s–60s.
  98. Howard G, Wills S, Kresge C, McConnell D, Balasubramaniam M, Decker D. The effects of vaginal estrogens on plasma estradiol levels in women taking aromatase inhibitors. Breast Cancer Res Treat. 2007;106(1):S155;[abstract 3085]
  99. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996;23:259–263
  100. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol. 1997;15:969–973
  101. Derzko C, Elliott S, Lam W. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol. 2007;14(Suppl. 1):S20–S40
  102. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomized double-blind placebo-controlled trial. Lancet. 2005;366:818–824
  103. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;95:1758–1764
  104. Biglia N, Torta R, Roagna R, et al. Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. Maturitas. 2005;52:78–85
  105. Goldberg RM, Loprinzi CL, O’Fallan JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol. 1994;12:155–178
  106. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Eng J Med. 1994;331:347–352
  107. Loprinzi CL, Barton DL, Sloan JA, et al. Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience. Menopause. 2008;15:655–669
  108. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97:30–39
  109. Staropoli CA, Flaws JA, Bush TL, Moulton AW. Predictors of menopausal hot flashes. J Womens Health. 1998;7:1149–1155
  110. Harris PF, Remington PL, Trentham-Dietz A, Allen CI, Newcomb P,A. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage. 2002;23:501–509
  111. Deng G, Vickers AJ, Yeung S, et al. Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients. J Clin Oncol. 2007;25:5584–5590
  112. Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol. 2005;23:1636–1643
  113. Moy B, Elliott CR, Chapman J-AW, et al. NCIC CTG MA.27: menopausal symptoms of ethnic minority women. Breast Cancer Res Treat. 2006;100(1):S144;[abstract 3059]
  114. Goss PE. Extending the benefits of adjuvant therapy in early HR+ breast cancer. Breast Cancer Res Treat. 2008;112(Suppl 1):45–52
  115. Mamounas EP, Lembersky B, Jeong JH, et al. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer. 2006;7:416–421
  116. De Boer R, Burris H, Monnier A, et al. Oon behalf of the H2H trial steering committee The Head to Head trial: letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. J Clin Oncol. 2006;24(18S):582s;[abstract 10672]

PII: S0305-7372(09)00192-3

doi: 10.1016/j.ctrv.2009.12.010

Cancer Treatment Reviews
Volume 36, Issue 3 , Pages 249-261 , May 2010

Article Tools